Thomas A Mace, PhD
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forAs a member of the Translational Therapeutics Program at the OSUCCC – James, my research is focused on translational tumor immunology, namely discovering new targets and pathways in the tumor microenvironment that can lead to improvements in patient responses to immune-based therapeutics. In particular, my laboratory seeks to better understand the pancreatic tumor microenvironment and determine the mechanisms of resistance to immune-based therapeutics.
I am investigating how cell surface proteins (e.g., CD200) expressed by the tumor and stromal cells promote the expansion and function of immunosuppressive cell types like myeloid-derived suppressor cells (MDSC), as well as how these immunosuppressive immune populations affect cancer-induced cachexia, a debilitating syndrome in patients with pancreatic cancer. My laboratory is also investigating dietary nutritional intervention to modulate inflammation in chronic diseases and cancer.
Many immunosuppressive pathways observed in pancreatic cancer are also observed in other inflammatory diseases, such as chronic pancreatitis. I believe that neutralizing aberrant inflammatory responses may be a viable first line of defense against cancer.
One very interesting approach to limiting inflammation lies in the use of dietary intervention with foods possessing chemopreventive activity. My research has shown that active metabolites from dietary compounds such as soy, black raspberries and tomatoes can alter inflammatory factors and immune populations. This preliminary work has led to a USDA-AFRI foundation grant on a soy/tomato-enriched diet as a modulator of inflammation in men with obesity. My laboratory has shown that these diets can also modulate the severity and inflammation of pancreatitis in pre-clinical animal models. The ultimate goal is to discover and identify novel immunological pathways that we can target to improve responses in patients with cancer and inflammatory diseases.
I have authored or co-authored several articles in peer-reviewed publications, such as Pancreas, Cancer Research, Cancer Immunology Immunotherapy and Scientific Reports. My laboratory is currently funded by a Pelotonia Idea Grant.
Research Interests
More info for- Lung Neoplasms
- Pancreatic Neoplasms
- Pancreatitis, Chronic
- Immunosuppression
Education & Training
More info forGraduate Program - PhD
- Roswell Park Cancer Institute
Buffalo, NY
USA
Undergraduate Degree - BS
- Canisius College
Buffalo, NY
USA
- Roswell Park Cancer Institute
Academic Office & Contact Information
More info forAcademic Office:
Twelfth Ave, 395 W
395 W 12th Ave
Columbus, Ohio 43210-1267Phone:
614-366-3247Email:
mace.75@osu.eduPublications
More info forMay 22, 2024Physical Activity Decreases Inflammation and Delays Development of Obesity-Associated Pancreatic Ductal Adenocarcinoma.
Pita-Grisanti V, Vélez-Bonet E, Chasser K, Hurst Z, Liette A, Vulic G, Dubay K, Lahooti A, Badi N, Ueltschi O, Gumpper-Fedus K, Hsueh HY, Lahooti I, Chavez-Tomar M, Terhorst S, Knoblaugh SE, Cao L, Huang W, Coss CC, Mace TA, Choueiry F, Hinton A, Culp S, Mitchell JM, Schmandt R, Onstad Grinsfelder M, Basen-Engquist K, Cruz-Monserrate Z
Cancer Res
April 15, 2024CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.
Wedig J, Jasani S, Mukherjee D, Lathrop H, Matreja P, Pfau T, D'Alesio L, Guenther A, Fenn L, Kaiser M, Torok MA, McGue J, Sizemore GM, Noonan AM, Dillhoff ME, Blaser BW, Frankel TL, Culp S, Hart PA, Cruz-Monserrate Z, Mace TA
Cancer Immunol Immunother
January 26, 2024Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study.
Gumpper-Fedus K, Chasser K, Pita-Grisanti V, Torok M, Pfau T, Mace TA, Cole RM, Belury MA, Culp S, Hart PA, Krishna SG, Lara LF, Ramsey ML, Fisher W, Fogel EL, Forsmark CE, Li L, Pandol S, Park WG, Serrano J, Van Den Eeden SK, Vege SS, Yadav D, Conwell DL, Cruz-Monserrate Z, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
Clin Transl Gastroenterol
December 23, 2023Decoupling FcRn and Tumor Contributions to Elevated Immune Checkpoint Inhibitor Clearance in Cancer Cachexia.
Vu TT, Kim K, Manna M, Thomas J, Remaily B, Montgomery EJ, Costa T, Granchie L, Xie Z, Guo Y, Chen M, Castillo AMM, Kulp SK, Mo X, Nimmagadda S, Gregorevic P, Owen DH, Ganesan LP, Mace TA, Coss CC, Phelps MA
Pharmacol Res
November 3, 2023Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors.
Guo Y, Remaily BC, Thomas J, Kim K, Kulp SK, Mace TA, Ganesan LP, Owen DH, Coss CC, Phelps MA
Clin Cancer Res
August 18, 2023Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression.
Mukherjee D, Chakraborty S, Bercz L, D'Alesio L, Wedig J, Torok MA, Pfau T, Lathrop H, Jasani S, Guenther A, McGue J, Adu-Ampratwum D, Fuchs JR, Frankel TL, Pietrzak M, Culp S, Strohecker AM, Skardal A, Mace TA
iScience
March 7, 2023Dual IL-6 and CTLA-4 blockade regresses pancreatic tumors in a T cell and CXCR3-dependent manner.
Ware MB, Phillips M, McQuinn C, Zaidi MY, Knochelmann HM, Greene E, Robinson BS, Herting CJ, Mace TA, Chen Z, Zhang C, Farren MR, Ruggieri AN, Bowers JS, Shakya R, Farris AB, Young G, Carson Iii WE, El-Rayes B, Paulos CM, Lesinski GB
JCI Insight
December 15, 2022The phase 1/2 trial of indomethacin in chronic pancreatitis (The PAIR trial): Protocol for a parallel multi-center randomized controlled trial.
Han S, Conwell DL, Li L, Cervantes A, Hart PA, Cruz-Monserrate Z, Hao W, Lesinski GB, Mace T, Palermo TM, Saloman JL, Yadav D, Vege SS, Topazian M, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC)
Pancreatology
October 22, 2022Nucleoside transporters and immunosuppressive adenosine signaling in the tumor microenvironment: Potential therapeutic opportunities.
Kaur T, Weadick B, Mace TA, Desai K, Odom H, Govindarajan R
Pharmacol Ther
July 4, 2022Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer.
Issa M, Tang J, Guo Y, Coss C, Mace TA, Bischof J, Phelps M, Presley CJ, Owen DH
Expert Rev Anticancer Ther
June 25, 2022The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA
Int J Mol Sci
January 8, 2022Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH
Clin Lung Cancer
July 1, 2021Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans.
Castillo AMM, Vu TT, Liva SG, Chen M, Xie Z, Thomas J, Remaily B, Guo Y, Subrayan UL, Costa T, Helms TH, Irby DJ, Kim K, Owen DH, Kulp SK, Mace TA, Phelps MA, Coss CC
JCSM Rapid Commun
June 23, 2021A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB
Cancer Immunol Immunother
January 1, 2021Delayed Processing of Secretin-Induced Pancreas Fluid Influences the Quality and Integrity of Proteins and Nucleic Acids.
Cruz-Monserrate Z, Gumpper K, Kaul S, Badi N, Terhorst S, Dubay K, Lesinski GB, Fisher W, McElhany A, Lara LF, Krishna S, Mace T, Higuita-Castro N, Ortega-Pineda L, Freitas MA, Hinton A, Yadav D, Hart PA, Pandol SJ, Ahmed S, Fatou B, Steen H, Conwell DL, Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer##
Pancreas
June 6, 2020Reduction of inflammation in chronic pancreatitis using a soy bread intervention: A feasibility study.
Ahn-Jarvis J, Lombardo E, Cruz-Monserrate Z, Badi N, Crowe O, Kaul S, Komar H, Krishna SG, Lesinski GB, Mace TA, Ramsey ML, Roberts K, Stinehart K, Traczek M, Conwell DL, Vodovotz Y, Hart PA
Pancreatology
June 1, 2020CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson Iii WE, Mace TA
J Immunother Cancer
May 19, 2020Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R, Stiff A, Quiroga D, McQuinn C, Li Z, Nitta H, Savardekar H, Benner B, Ramaswamy B, Lustberg M, Layman RM, Macrae E, Kassem M, Williams N, Sardesai S, VanDeusen J, Stover D, Cherian M, Mace TA, Yu L, Duggan M, Carson WE
BMC Cancer